Activation of the mutation of the receptor tyrosine kinase (RTK) c-KIT and related signaling partners has been described as an oncogenic driver in the molecular pathogenesis of various types of human malignancies, including mast cell activation disorders, gastrointestinal stromal tumors, melanomas, and acute myeloid leukemia (AML) [3–5]. The gene discussed is NTRK1; the disease is acute myeloid leukemia.